Longterm Treatment with Endothelin Receptor Antagonist Bosentan and Iloprost Improves Fingertip Blood Perfusion in Systemic Sclerosis

被引:53
|
作者
Cutolo, Maurizio [1 ]
Ruaro, Barbara [1 ,2 ]
Pizzorni, Carmen [1 ,2 ]
Ravera, Francesca [1 ,2 ]
Smith, Vanessa [3 ]
Zampogna, Giuseppe [1 ,2 ]
Paolino, Sabrina [1 ,2 ]
Seriolo, Bruno [1 ,2 ]
Cimmino, Marco [1 ,2 ]
Sulli, Alberto [1 ,2 ]
机构
[1] Univ Genoa, Res Lab, I-16132 Genoa, Italy
[2] Univ Genoa, Acad Div Clin Rheumatol, Dept Internal Med, I-16132 Genoa, Italy
[3] Ghent Univ Hosp, Dept Rheumatol, Ghent, Belgium
关键词
SYSTEMIC SCLEROSIS; RAYNAUD PHENOMENON; LASER DOPPLER FLOWMETRY; NAILFOLD VIDEOCAPILLAROSCOPY; ENDOTHELIN-1; ANTAGONIST; ILOPROST; RAYNAUDS-PHENOMENON; NAILFOLD VIDEOCAPILLAROSCOPY; CAPILLAROSCOPIC ANALYSIS; MICROVASCULAR CHANGES; DISEASE; MANAGEMENT; SEVERITY; DAMAGE;
D O I
10.3899/jrheum.131284
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To evaluate the longterm effects of endothelin-1 (ET-1) antagonism on peripheral blood perfusion (PBP) in patients with systemic sclerosis (SSc). Methods. Twenty-six patients with SSc already receiving cyclic intravenous iloprost (ILO) for severe Raynaud phenomenon were enrolled. Thirteen patients continued the treatment for a further 3 years (ILO group) and 13 patients, because of the appearance of digital ulcers, received in addition bosentan (BOS; 125 mg twice/day) for 3 years (ILO + BOS group). Both PBP at fingertips and nailfold microangiopathy were evaluated yearly by laser Doppler flowmetry and nailfold videocapillaroscopy, respectively. Results. A progressive significant increase of PBP was observed in the ILO + BOS group during the 3 followup years (p = 0.0007, p = 0.0002, p = 0.01, respectively). In contrast, an insignificant progressive decrease of PBP was observed in the ILO group. Difference of perfusion between the PBP evaluations at basal temperature and at 36 degrees C (to test capillary dilation capacity), was found progressively decreased during the 3-year followup only in the ILO group (p = 0.05, p = 0.26, p = 0.09, respectively). A progressive increase of nailfold capillary number was observed only in the ILO + BOS group after 2 and 3 years of followup (p = 0.05). Conclusion. Longterm treatment of SSc patients with ET-1 antagonism, in combination with ILO, seems to increase fingertip blood perfusion, as well as both capillary dilation capacity and number.
引用
收藏
页码:881 / 886
页数:6
相关论文
共 50 条
  • [31] Treatment of severe complications of Fontan circulation with Endothelin1 dual (A and B) receptor antagonist Bosentan
    Milanesi, O.
    Scarabeo, V.
    Maschietto, N.
    Biffanti, R.
    Patuelli, G.
    EUROPEAN HEART JOURNAL, 2009, 30 : 808 - 808
  • [32] The endothelin-receptor antagonist bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects
    Sitbon, O
    Beghetti, M
    Petit, J
    Iserin, L
    Humbert, M
    Gressin, V
    Simonneau, G
    EUROPEAN HEART JOURNAL, 2004, 25 : 22 - 22
  • [33] No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs
    Rasmussen, M
    Poulsen, PH
    Treiber, A
    Delahaye, S
    Tankisi, A
    Cold, GE
    Therkelsen, K
    Gjedde, A
    Astrup, J
    ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2003, 47 (02) : 200 - 207
  • [34] Bosentan, a new endothelin receptor antagonist: Prediction of the systemic plasma clearance in man from combined in vivo and in vitro data
    Ubeaud, G
    Schmitt, C
    Jaeck, D
    Lave, T
    Coassolo, P
    XENOBIOTICA, 1995, 25 (12) : 1381 - 1390
  • [35] IMAGING AND RHEUMATIC DISEASES: CORRELATION BETWEEN FINGERTIP BLOOD PERFUSION AND NAILFOLD CAPILLARY IMPAIRMENT IN SYSTEMIC SCLEROSIS
    Cutolo, M.
    Ferrone, C.
    Pizzorni, C.
    Ravera, F.
    Zampogna, G.
    Sulli, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 : A49 - A49
  • [36] Endothelin receptor antagonist tezosentan improves mesenteric blood flow in septic shock models
    Erdem, A.
    Sevgili, A. M.
    Akbiyik, F.
    Iskit, A. B.
    Balkanci, Z. D.
    Guc, M. O.
    FEBS JOURNAL, 2006, 273 : 146 - 146
  • [37] A mixed ET(A)-, ET(B)-receptor antagonist (Bosentan) improves hepatic microvascular perfusion after warm ischemia.
    Koeppel, TA
    Thies, JC
    Gebhard, MM
    Otto, G
    Post, S
    HEPATOLOGY, 1996, 24 (04) : 1224 - 1224
  • [38] The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial
    Rafnsson, A.
    Bohm, F.
    Settergren, M.
    Gonon, A.
    Brismar, K.
    Pernow, J.
    DIABETOLOGIA, 2012, 55 (03) : 600 - 607
  • [39] The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial
    A. Rafnsson
    F. Böhm
    M. Settergren
    A. Gonon
    K. Brismar
    J. Pernow
    Diabetologia, 2012, 55 : 600 - 607
  • [40] INTRAVENOUS BOSENTAN, AN ENDOTHELIN-1 RECEPTOR ANTAGONIST, IMPROVES CARDIAC-PERFORMANCE IN DOGS WITH CHRONIC HEART-FAILURE
    SHIMOYAMA, H
    SABBAH, HN
    TANIMURA, M
    SHEVLYAGIN, S
    BORZAK, S
    GOLDSTEIN, S
    CIRCULATION, 1995, 92 (08) : 143 - 143